Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
ESMO Highlights
Meeting Highlights
ESMO Highlights
Chemotherapy After Progression on Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
A Network Meta-Analysis Comparing Efficacy of First-Line Maintenance PARP Inhibitors
Read More
Meeting Highlights
ESMO Highlights
Results from the GEICO1601-ROLANDO Phase 2 Trial Evaluating Combination of Olaparib and PLD in Platinum-Resistant Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Results of 5-Year Follow-Up of Maintenance Olaparib in Patients with Newly Diagnosed, Advanced Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Olaparib + Durvalumab and Bevacizumab: Initial Results in Patients with Non-Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Phase 2 Trial of Olvi-Vec in Heavily Pretreated Platinum-Resistant/Refractory Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer from PRIMA/ENGOT-OV26/GOG-3012
Read More
Meeting Highlights
ESMO Highlights
Olaparib Maintenance Therapy in Clinical Practice: Quality-of-Life Interim Results of the C-PATROL Study in Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Response to Olaparib Monotherapy in Relapsed Ovarian Cancer by HRR Gene Mutational Status and HRD Scarring Analysis
Read More
Meeting Highlights
ESMO Highlights
Timing of Adverse Events During Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer in Phase 3 Study
Read More
1
2
3
4
5
Page 2 of 5
Results 11 - 20 of 44